FULC Q4 2025 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FULCFulcrum Therapeutics, Inc.

$436M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$300,000

Operating Income

-$23M

Net Income

-$20M

EPS (Diluted)

$-0.31

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$366M

Total Liabilities

$17M

Stockholders' Equity

$349M

Cash & Equivalents

$198M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$300,000	-$369,000	+181.3%
Operating Income	-$23M	-$19M	-16.8%
Net Income	-$20M	-$17M	-22.7%